Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Docetaxel|DRUG: Nintedanib|DRUG: Docetaxel: increase of the dose
Sponsor: Centre Oscar Lambret
Collaborators: Boehringer Ingelheim